Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

111In DOTA h 11B6

Next Previous
Drug Profile

111In DOTA h 11B6

Alternative Names: 111-indium labelled h 11B6 - Invicro/Janssen Research & Development; 111In-DOTA-h11B6; 111In-DOTA_h11B6

Latest Information Update: 28 Oct 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tomopath Inc.
  • Developer Invicro; Janssen Research & Development
  • Class Antineoplastics; Drug conjugates; Imaging agents; Immunoconjugates; Monoclonal antibodies; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Prostate cancer

Most Recent Events

  • 28 Oct 2023 No recent reports of development identified for preclinical development in Prostate-cancer in USA (IV, Injection)
  • 28 Nov 2022 No recent reports of development identified for phase-0 development in Prostate-cancer(Diagnosis, Hormone refractory, Metastatic disease) in USA (IV, Injection)
  • 18 Sep 2019 Phase-0 for Prostate cancer (Metastatic disease, Hormone refractory, Diagnosis) in USA (IV) (NCT04116164)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top